BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24951114)

  • 1. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
    Kieran MW
    Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
    Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
    Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
    Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
    Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
    Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
    J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation.
    Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential use of CXCL12/CXCR4 and sonic hedgehog pathways as therapeutic targets in medulloblastoma.
    Amarante MK; Vitiello GAF; Rosa MH; Mancilla IA; Watanabe MAE
    Acta Oncol; 2018 Sep; 57(9):1134-1142. PubMed ID: 29771176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
    Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U
    Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.
    Yao YL; Wang YX; Yang FC; Wang C; Mao M; Gai QJ; He J; Qin Y; Yao XX; Lan X; Zhu J; Lu HM; Zeng H; Yao XH; Bian XW; Wang Y
    CNS Neurosci Ther; 2022 Jul; 28(7):1033-1044. PubMed ID: 35419951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells.
    Scheidt T; Alka O; Gonczarowska-Jorge H; Gruber W; Rathje F; Dell'Aica M; Rurik M; Kohlbacher O; Zahedi RP; Aberger F; Huber CG
    Cell Commun Signal; 2020 Jun; 18(1):99. PubMed ID: 32576205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.
    Al-Halabi H; Nantel A; Klekner A; Guiot MC; Albrecht S; Hauser P; Garami M; Bognar L; Kavan P; Gerges N; Shirinian M; Roberge D; Muanza T; Jabado N
    Acta Neuropathol; 2011 Feb; 121(2):229-39. PubMed ID: 21107850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
    Menyhárt O; Győrffy B
    Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth.
    Yang F; Rodriguez-Blanco J; Long J; Swiderska-Syn M; Wynn DT; Li B; Shen C; Nayak A; Ban Y; Sun X; Suter RK; McCrea HJ; Capobianco AJ; Ayad NG; Robbins DJ
    Mol Cancer Res; 2022 Nov; 20(11):1598-1610. PubMed ID: 35925047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted Functions of Rab23 on Primary Cilium-Mediated and Hedgehog Signaling-Mediated Cerebellar Granule Cell Proliferation.
    Hor CHH; Lo JCW; Cham ALS; Leong WY; Goh ELK
    J Neurosci; 2021 Aug; 41(32):6850-6863. PubMed ID: 34210780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth.
    Di Magno L; Manzi D; D'Amico D; Coni S; Macone A; Infante P; Di Marcotullio L; De Smaele E; Ferretti E; Screpanti I; Agostinelli E; Gulino A; Canettieri G
    Cell Cycle; 2014; 13(21):3404-13. PubMed ID: 25485584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.